Analgesics
31
2
2
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.5%
2 terminated out of 31 trials
88.2%
+1.7% vs benchmark
32%
10 trials in Phase 3/4
27%
4 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (31)
Natural History of Depression, Bipolar Disorder and Suicide Risk
Pregabalin vs. Gabapentin on Reducing Opioid Usage
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Comparison of 2 Different Methods in Infraclavicular Block
U/S Guided Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block vs Type 2 Pectoral Nerve Block
Rescue Quadratus Lumborum Blocks for Post-cesarean Pain
Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion
Opioid-free Anesthesia in Thyroidectomies
Opioid-free Anesthesia in Laparoscopic Cholecystectomies
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Opioid Sparing Anesthesia in Cervical Spine Surgery
Opioid Sparing Anesthesia in Lumbar Spine Surgery
Lidocaine and Magnesium and Ketamine in Gynecological Surgery
Opioid-free Anesthesia With a Mixture of Dexmedetomidine-lidocaine-ketamine
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Analgesia in ÖAMTC Helicopter Emergency Service in Austria